SION
Sionna Therapeutics, Inc.
SION
Sionna Therapeutics, Inc.
San Diego, California--(Newsfile Corp. - August 20, 2026) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutic
Sionna Therapeutics told investors its SION-719 program was on track; the Phase 2a Trial Failed Key Endpoint and stock lost roughly 90% of its value. NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Sionna The
Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue develo